{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 64,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Uses a visual icon-grid to represent market expansion.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/24",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.85,
        "x": 0.11,
        "y": 0.18
      },
      "kind": "image",
      "text": "Today - CAR-T Treatment Options",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6180752d-0dbd-4e77-bd52-7a6fbcda5784",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.85,
        "x": 0.11,
        "y": 0.58
      },
      "kind": "image",
      "text": "NXC-201 Treatment Options",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ab87649-1d2e-4804-b50f-3b90ca9e1c8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.12,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "Today: CAR-T is accessible at only 5% of US hospitals, mostly academic research centers in major cities",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7713ae69-6e02-4366-b237-ebfb8e8e8ffe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.14,
        "y": 0.74
      },
      "kind": "paragraph",
      "text": "Future: NXC-201 potentially accessible at many more US hospitals, academic research centers in cities + regional medical centers and clinics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c1df9a5-60e2-4778-86f6-6b2ca1d53ddf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.02,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Sharma A, et al, Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients, Transplant Cell Ther. 2023 Feb;29(2):108.e1-108.e7. doi: 10.1016/j.jtct.2022.11.004. Epub 2022 Nov 9. PMID: 36371048.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9f20e8c-d8f4-424c-9067-e623c9681168",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Outpatient Access To NXC-201 Potentially Increases CAR-T Addressable Market by 10-20x",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3eb1ec61-4079-4d0d-83f8-28ed6093e8e3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "iconography",
      "slug": null,
      "matchId": "6d6b827e-17ab-42b6-8d24-0a77e0304f11",
      "evidence": "Visual representation of market expansion using icon grids",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 29,
      "from": 24,
      "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    },
    {
      "to": 27,
      "from": 23,
      "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The clinical development plan and upcoming catalysts are outlined.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}